A Phase 3 interventional study of Humira (adalimumab) in Psoriasis, sponsored by Abbott. Completed at 27 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-04-11.
Sponsored by Abbott · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies testing adalimumab in Psoriasis — 6 open to participants now, 6 under way, 1 of them phase 3. Adalimumab · Psoriasis.
Among the 48 studies testing adalimumab in Psoriasis, this one is the 21st largest by enrollment, is one of 2 that started in 2007, is one of 26 in phase 3, and was the 4th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →6 of the 48 studies testing adalimumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:
South Valley University · Sites in Egypt
Ages 18–70 · Healthy volunteers
Mabscale, LLC · Sites in Russian Federation
Ages 18–65
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Ages 4–17
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 27 · Phase 4 11
First in 2003; this study’s year is marked. 2 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 203 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 148 across the 48 interventional studies. Of the 41 that completed or were terminated, 27 (66%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 48 have an industry lead sponsor. The 10 most frequent:
Abbott is the lead sponsor of 361 studies on the registry; 1 is open to participants now.
16 studies in Psoriasis by Abbott: none open now, none under way, none of them phase 3. Of 15 finished, 8 (53%) have results posted.
Among the 16 studies in Psoriasis by Abbott, this one is the 5th largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2007, is one of 6 in phase 3, and was the 5th registered.
Abbott’s Psoriasis studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 48 studies testing adalimumab in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Abbott’s 16 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the safety profile, the effectiveness and the economic impact of adalimumab when used for the treatment of subjects with active plaque psoriasis who have not adequately responded to prior psoriasis therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject has failed to respond to, is intolerant to or has for at least two of the following therapies:
If female, subject is either not of , defined as for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or is of childbearing potential and practicing one of the following methods of :
Exclusion Criteria:
Topical therapies:
Oral or injectable corticosteroids therapies:
Phototherapies
Systemic Therapies:
Subject cannot discontinue the following systemic psoriasis therapies:
Subject has a history of cancer or lymphoproliferative disease other than:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Humira (adalimumab)
Study drug will be provided as a sterile, preservative-free solution for subcutaneous injection, contained in a pre-filled syringe housed in a pen device (pre-filled pen). Loading dose of 80 mg of adalimumab subcutaneously (sc) at Baseline, and 40 mg of adalimumab sc at Week 1, followed by 40 mg of adalimumab sc every other week (eow) for 24 weeks.
Also known as: ABT-D2E7, adalimumab, Humira
Number of Subjects With Psoriasis Area and Severity Index (PASI) 75 Response at 16 Weeks
PASI 75 is a 75% or greater improvement on the Psoriasis Area and Severity Index (PASI). The PASI scale runs from 0-72, where 0 = no psoriasis and 72 = complete erythroderma of the severest possible degree
Time frame: 16 weeks
Mean Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at 16 and 24 Weeks
Mean change in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI score ranges from 0-72, where 0 = no psoriasis and 72 = complete erythroderma of the severest possible degree
Time frame: 16 and 24 weeks
Mean Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at 16 and 24 Weeks
Mean percent change in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI score ranges from 0-72, where 0 = no psoriasis and 72 = complete erythroderma of the severest possible degree.
Time frame: 16 and 24 weeks
Number of Subjects With Improvement in Physician's Global Assessment for Psoriasis (PGA)
Number of subjects with improvement on the Physician's Global Assessment for Psoriasis (PGA). The PGA is a 6-point scale used to measure the severity of disease at the time of the physician's evaluation of the subject, where 0 = clear and 6 = very severe. Improvement is defined as a reduction in PGA score.
Time frame: 16 and 24 weeks
Number of Subjects Achieving a Clinical Response Defined as a Physician's Global Assessment for Psoriasis (PGA) of "Clear" or "Clear or Minimal"
Number of subjects achieving a response of "Clear" or "Clear or Minimal" on the Physician's Global Assessment for Psoriasis. This is a 6-point scale used to measure the severity of disease at the time of the physician's evaluation of the subject. The degree of overall severity is rated as follows: 0-Clear, 1-Minimal, 2-Mild, 3-Moderate, 4-severe, 5-very severe.
Time frame: 16 and 24 weeks
Mean Change From Baseline in Physician Global Assessment of Arthritic Disease Activity at 16 and 24 Weeks
Mean Change from Baseline in Physician Global Assessment of Arthritic Disease Activity as measured on a 100-mm visual analog scale where 0 mm = no arthritis activity and 100 mm = extremely active arthritis.
Time frame: 16 and 24 weeks
Number of Subjects With Psoriasis Area and Severity Index (PASI) 50/75/90/100 Response
PASI 50/75/90/100 is a \>=50% / \>=75% / \>=90% / 100% improvement on the Psoriasis Area and Severity Index (PASI). The PASI scale runs from 0-72, where 0 = no psoriasis and 72 = complete erythroderma of the severest possible degree.
Time frame: 16 and 24 weeks
Mean Change From Baseline in Tender Joint Count at 16 and 24 Weeks
Mean change in the number of tender joints from Baseline. 78 joints were evaluated for tenderness, including all 76 joints evaluated for swelling plus the hip joints.
Time frame: 16 and 24 weeks
Mean Change From Baseline in Swollen Joint Count at 16 and 24 Weeks
Mean change in the number of swollen joints from Baseline. 76 joints were evaluated for swelling, corresponding to all joints evaluated for tenderness except for the hip joints.
Time frame: 16 and 24 weeks
Mean Change From Baseline in Patient's Global Assessment of Joint Pain at 16 and 24 Weeks
Mean change in the Patient's Global Assessment of Joint Pain from Baseline, as assessed on a 100-mm visual analog scale where 0 mm = no pain and 100 mm = pain as bad as it could be.
Time frame: 16 and 24 weeks
Mean Change From Baseline in the Dermatology Life Quality Index (DLQI) at 16 and 24 Weeks
Mean change in the Dermatology Life Quality Index (DLQI) from Baseline. The questionnaire contains 10 questions and is scored from 0-30, where 0 = total lack of impairment and 30 = my life is very much impaired; the minimum clinically important difference is 2.3 to 5.7 point change.
Time frame: 16 and 24 weeks
Number of Subjects Achieving a Dermatology Life Quality Index (DLQI) = 0
Number of subjects achieving a Dermatology Life Quality Index (DLQI) score of 0 (indicating total lack of impairment). The DLQI consists of 10 questions and is scored from 0-30, where 0 = total lack of impairment and 30 = my life is very much impaired.
Time frame: 16 and 24 weeks
Mean Change From Baseline in Beck Depression Inventory (BDI-II) at 16 and 24 Weeks
Change in the Beck Depression Inventory from Baseline. The BDI-II contains 21 questions and is scored from 0-63; higher scores indicate more severe depression symptoms.
Time frame: 16 and 24 weeks
Change From Baseline on the EuroQol (EQ-5D) Quality of Life Questionnaire
Time frame: 16 and 24 weeks
Change in Productivity Outcomes and Costs From Baseline as Measured by the Health and Labour Questionnaire (HLQ)
Time frame: 16 and 24 weeks
Change in Resource Utilization Outcomes and Costs From Baseline as Measured by the Health Care Resource (HCR) Questionnaire
Time frame: 16 and 24 weeks
| Milestone | Adalimumab 40 mg Eow |
|---|---|
| Started | 203 |
| Completed | 179 |
| Not completed | 24 |
PASI 75 is a 75% or greater improvement on the Psoriasis Area and Severity Index (PASI). The PASI scale runs from 0-72, where 0 = no psoriasis and 72 = complete erythroderma of the severest possible degree
| participants | Adalimumab 40 mg Eow - 16 Weeks |
|---|---|
| Responder | 144 |
| Non-responder | 47 |
Mean change in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI score ranges from 0-72, where 0 = no psoriasis and 72 = complete erythroderma of the severest possible degree
| unit on a scale | Adalimumab 40 mg Eow - 16 Weeks | Adalimumab 40 mg Eow - 24 Weeks |
|---|---|---|
| Change from Baseline | -15.9 ± 7.55 | -16.1 ± 7.46 |
Mean percent change in Psoriasis Area and Severity Index (PASI) score from Baseline. PASI score ranges from 0-72, where 0 = no psoriasis and 72 = complete erythroderma of the severest possible degree.
| percent change | Adalimumab 40 mg Eow - 16 Weeks | Adalimumab 40 mg Eow - 24 Weeks |
|---|---|---|
| Mean Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at 16 and 24 Weeks | -81.5 ± 23.63 | -83.0 ± 23.47 |
Number of subjects with improvement on the Physician's Global Assessment for Psoriasis (PGA). The PGA is a 6-point scale used to measure the severity of disease at the time of the physician's evaluation of the subject, where 0 = clear and 6 = very severe. Improvement is defined as a reduction in PGA score.
| participants | Adalimumab 40 mg Eow - 16 Weeks | Adalimumab 40 mg Eow - 24 Weeks |
|---|---|---|
| Number of Subjects With Improvement in Physician's Global Assessment for Psoriasis (PGA) | 174 | 164 |
Number of subjects achieving a response of "Clear" or "Clear or Minimal" on the Physician's Global Assessment for Psoriasis. This is a 6-point scale used to measure the severity of disease at the time of the physician's evaluation of the subject. The degree of overall severity is rated as follows: 0-Clear, 1-Minimal, 2-Mild, 3-Moderate, 4-severe, 5-very severe.
| participants | Adalimumab 40 mg Eow - 16 Weeks | Adalimumab 40 mg Eow - 24 Weeks |
|---|---|---|
| Subjects achieving "Clear" | 53 | 59 |
| Subjects achieving "Clear or Minimal" | 111 | 121 |
Mean Change from Baseline in Physician Global Assessment of Arthritic Disease Activity as measured on a 100-mm visual analog scale where 0 mm = no arthritis activity and 100 mm = extremely active arthritis.
| units on a scale | Adalimumab 40 mg Eow - 16 Weeks | Adalimumab 40 mg Eow - 24 Weeks |
|---|---|---|
| Mean Change From Baseline in Physician Global Assessment of Arthritic Disease Activity at 16 and 24 Weeks | -18.7 ± 23.48 | -20.9 ± 23.32 |
PASI 50/75/90/100 is a \>=50% / \>=75% / \>=90% / 100% improvement on the Psoriasis Area and Severity Index (PASI). The PASI scale runs from 0-72, where 0 = no psoriasis and 72 = complete erythroderma of the severest possible degree.
| participants | Adalimumab 40 mg Eow - 16 Weeks | Adalimumab 40 mg Eow - 24 Weeks |
|---|---|---|
| Subjects achieving PASI 50 | 169 | 163 |
| Subjects achieving PASI 75 | 144 | 140 |
| Subjects achieving PASI 90 | 100 | 102 |
| Subjects achieving PASI 100 | 49 | 58 |
Mean change in the number of tender joints from Baseline. 78 joints were evaluated for tenderness, including all 76 joints evaluated for swelling plus the hip joints.
| number of joints | Adalimumab 40 mg Eow - 16 Weeks | Adalimumab 40 mg Eow - 24 Weeks |
|---|---|---|
| Mean Change From Baseline in Tender Joint Count at 16 and 24 Weeks | -8.7 ± 13.57 | -8.7 ± 14.83 |
Mean change in the number of swollen joints from Baseline. 76 joints were evaluated for swelling, corresponding to all joints evaluated for tenderness except for the hip joints.
| number of joints | Adalimumab 40 mg Eow - 16 Weeks | Adalimumab 40 mg Eow - 24 Weeks |
|---|---|---|
| Mean Change From Baseline in Swollen Joint Count at 16 and 24 Weeks | -4.7 ± 5.35 | -4.9 ± 7.08 |
Mean change in the Patient's Global Assessment of Joint Pain from Baseline, as assessed on a 100-mm visual analog scale where 0 mm = no pain and 100 mm = pain as bad as it could be.
| units on a scale | Adalimumab 40 mg Eow - 16 Weeks | Adalimumab 40 mg Eow - 24 Weeks |
|---|---|---|
| Mean Change From Baseline in Patient's Global Assessment of Joint Pain at 16 and 24 Weeks | -20.9 ± 31.77 | -19.3 ± 32.02 |
Mean change in the Dermatology Life Quality Index (DLQI) from Baseline. The questionnaire contains 10 questions and is scored from 0-30, where 0 = total lack of impairment and 30 = my life is very much impaired; the minimum clinically important difference is 2.3 to 5.7 point change.
| units on a scale | Adalimumab 40 mg Eow - 16 Weeks | Adalimumab 40 mg Eow - 24 Weeks |
|---|---|---|
| Mean Change From Baseline in the Dermatology Life Quality Index (DLQI) at 16 and 24 Weeks | -9.8 ± 7.09 | -10.1 ± 7.26 |
Number of subjects achieving a Dermatology Life Quality Index (DLQI) score of 0 (indicating total lack of impairment). The DLQI consists of 10 questions and is scored from 0-30, where 0 = total lack of impairment and 30 = my life is very much impaired.
| participants | Adalimumab 40 mg Eow - 16 Weeks | Adalimumab 40 mg Eow - 24 Weeks |
|---|---|---|
| Number of Subjects Achieving a Dermatology Life Quality Index (DLQI) = 0 | 67 | 83 |
Change in the Beck Depression Inventory from Baseline. The BDI-II contains 21 questions and is scored from 0-63; higher scores indicate more severe depression symptoms.
| units on a scale | Adalimumab 40 mg Eow - 16 Weeks | Adalimumab 40 mg Eow - 24 Weeks |
|---|---|---|
| Mean Change From Baseline in Beck Depression Inventory (BDI-II) at 16 and 24 Weeks | -4.1 ± 6.56 | -4.3 ± 6.71 |
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Adalimumab 40 mg Eow | — | — | — |
| Event | Adalimumab 40 mg Eow |
|---|---|
| Myocardial infarctionCardiac disorders | 2/203 |
| Tongue oedemaGastrointestinal disorders | 1/203 |
| PericarditisCardiac disorders | 1/203 |
| DeathGeneral disorders | 1/203 |
| AppendicitisInfections and infestations | 1/203 |
| PneumoniaInfections and infestations | 1/203 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/203 |
| Renal vasculitisRenal and urinary disorders | 1/203 |
| Stevens-Johnson syndromeSkin and subcutaneous tissue disorders | 1/203 |
| Event | Adalimumab 40 mg Eow |
|---|---|
| Upper respiratory tract infectionInfections and infestations | 22/203 |
| NasopharyngitisInfections and infestations | 22/203 |
| InfluenzaInfections and infestations | 10/203 |
| HeadacheNervous system disorders | 10/203 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 8/203 |
| Injection site reactionGeneral disorders | 7/203 |
| PsoriasisSkin and subcutaneous tissue disorders | 7/203 |
| HypertensionVascular disorders | 7/203 |
| DiarrhoeaGastrointestinal disorders | 6/203 |
| NauseaGastrointestinal disorders | 6/203 |
| Age, Categorical(Participants) | Adalimumab 40 mg Eow |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 192 |
| >=65 years | 11 |
| Age Continuous(years) | Adalimumab 40 mg Eow |
|---|---|
| Mean | 45.5 ± 12.34 |
| Sex: Female, Male(Participants) | Adalimumab 40 mg Eow |
|---|---|
| Female | 79 |
| Male | 124 |
| Region of Enrollment(participants) | Adalimumab 40 mg Eow |
|---|---|
| Canada | 203 |
The record gives a start of Sep 2007 and a primary completion of Sep 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2009, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab